Efficacy of Immunization with a Combination of Serum and Recombinant Hepatitis B Vaccines

1993 ◽  
Vol 14 (8) ◽  
pp. 476-478 ◽  
Author(s):  
Karlyn K. Pearl ◽  
Ana A. Ortiz ◽  
William Pearl
Keyword(s):  
Hepatitis B ◽  
Healthcare Workers ◽  
Hepatitis B Surface Antigen ◽  
The United States ◽  
Recombinant Vaccine ◽  
Vaccine Group ◽  
Recombinant Hepatitis ◽  
The Third ◽  
Hepatitis B Vaccines ◽  
One Year

AbstractObjective:To evaluate the efficacy of giving a third dose of recombinant hepatitis B vaccine to healthcare workers who already had received two doses of serum-derived vaccine, which is no longer available in the United States.Design:Volunteers who already had received two standard doses of serum-derived vaccine were given a third dose of either serum or recombinant vaccine in a double-blind fashion. Antibodies to hepatitis B surface antigen were measured at the time of the third immunization, three months later, and one year after the third immunization.Setting:U.S. Army Medical Center, El Paso, Texas.Patients:One hundred healthy healthcare workers.Results:Three months after receiving the third immunization, the serum vaccine group had significantly higher titers than the recombinant vaccine group (P= 0.018). One year after receiving the third immunization, those who received the combined regimen had a mean hepatitis B surface antibody titer less than half that of those who received three doses of serum-derived vaccine. However, both regimens resulted in titers that are considered to confer immunity.Conclusions:A regimen that combines serum and recombinant hepatitis B vaccines may not produce as high an antibody level as three doses of the same vaccine. Those who began immunization with serum vaccine and concluded with recombinant vaccine should be monitored for an accelerated drop in serum antibodies.

scholarly journals Immunization aganist hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg)

1993 ◽  
Vol 35 (1) ◽  
pp. 89-92 ◽  
Author(s):  
C.R.B. Ferreira ◽  
C.F.T. Yoshida ◽  
L.A.C. Mercadante ◽  
D.F. Gomes ◽  
J.M. Oliveira ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Antibody Response ◽  
Recombinant Dna ◽  
Hepatitis B Surface Antigen ◽  
Vaccine Dose ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccine ◽  
Recombinant Hepatitis ◽  
The Third ◽  
Rural Zone

A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose , to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.

scholarly journals Effectiveness of recombinant hepatitis B vaccine with/without the passive hepatitis B immunoglobulin vaccine in babies whose mothers are hepatitis B surface antigen positive in a private missionary hospital

2021 ◽  
Vol 10 (6) ◽  
pp. 2383
Author(s):  
Olusanya Abiodun ◽  
Omobolaji Onibonoje ◽  
Oluwadara Ola ◽  
Sophie Ishola
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Developed Countries ◽  
Recombinant Vaccine ◽  
Hepatitis B Vaccine ◽  
Hbv Infection ◽  
Recombinant Hepatitis ◽  
Prospective Longitudinal Study ◽  
Hepatitis B Immunoglobulin ◽  
Prospective Longitudinal

Background: Hepatitis B infection is a potentially life-threatening liver infection. The burden is more in the less developed countries. Vaccination is the most cost-effective way to control hepatitis B virus (HBV) infection and its chronic complications globally. Active-passive immunoprophylaxis using hepatitis B immunoglobulin combined with recombinant hepatitis B vaccine is recommended for infants of women with chronic HBV infection. This study aimed to determine the effectiveness of the hepatitis B recombinant vaccine alone or combined with hepatitis B immunoglobulin.Methods: The study was a prospective longitudinal study. Patients were selected using a convenient sampling technique. The study spanned between 1 January 2017 and 31 December 2018. Data analysis was with SPSS version 21.Results: The unit recorded 1690 deliveries during the recruitment period, 70 eligible patients were recruited thus giving an incidence of 4.1%. 74.3% of the recruited patients were HBeAg negative while 25.7% were HBeAg positive. 52.9% of the babies had only recombinant HB recombinant vaccine while 47.1% had combined hepatitis B immunoglobulin and the recombinant vaccine at birth. The HBeAg status of mothers played a significant factor in the HBsAg positivity of babies two months after the completion of immunoprophylaxis against HBV.Conclusions: Giving recombinant HBV vaccine in combination with the HBV immunoglobulin is the standard practice, this may not always be so based on the findings from this study. However, the population studied is too small to make a categorical statement thus a larger population needs to be studied. 

scholarly journals Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination

2004 ◽  
Vol 46 (2) ◽  
pp. 103-107 ◽  
Author(s):  
José Luís da Silveira Baldy ◽  
Gerson Zanetta de Lima ◽  
Helena Kaminami Morimoto ◽  
Edna Maria Vissoci Reiche ◽  
Tiemi Matsuo ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Geometric Mean ◽  
The Other ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
The Third ◽  
B Virus ◽  
Adult Vaccination ◽  
Hepatitis B Vaccines

We evaluated the immunogenicity of three recombinant hepatitis B vaccines, one Brazilian (Butang, Instituto Butantan) and two Korean vaccines (Euvax-B, LG Chemical Ltd. and Hepavax-Gene, Greencross Vaccine Corp.), administered intramuscularly to students aged 17 to 19 years in three 10-µg doses (corresponding to half the amount of antigen routinely used for adult vaccination) at intervals of one month between the first and second dose, and of four months between the second and third dose. A total of 316 students non-reactive for any serological marker of hepatitis B virus infection were vaccinated: 77 (24.4%) with the Butang vaccine, 71 (22.5%) with Euvax-B, 85 (26.9%) with Hepavax-Gene and, for comparison, 83 (26.2%) with Engerix-B (GlaxoSmithKline), whose efficacy in young adults at the dose used here has been confirmed in previous studies. Similar seroconversion rates (anti-HBs > 10 mIU/mL about one month after application of the third dose) were obtained for the Butang, Euvax-B, Hepavax-Gene and Engerix-B vaccines (96.2%, 98.6%, 96.5% and 97.6%, respectively). The frequency of good responders (anti-HBs > 100 mIU/mL) was also similar among students receiving the four vaccines (85.8%, 91.6%, 89.4% and 89.2%, respectively). The geometric mean titers (GMT) of anti-HBs about one month after the third dose obtained with these vaccines were 727.78 ± 6.46 mIU/mL, 2009.09 ± 7.16 mIU/mL, 1729.82 ± 8.85 mIU/mL and 2070.14 ± 11.69 mIU/mL, respectively. The GMT of anti-HBs induced by the Euvax-B and Engerix-B vaccines were higher than those obtained with the Butang vaccine (p < 0.05); this difference was not significant when comparing the other vaccines two-by-two. No spontaneous adverse effects attributable to the application of any dose of the four vaccines were reported.

scholarly journals 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S562-S562
Author(s):  
Robert Gish ◽  
Vincent Streva
Keyword(s):  
Hepatitis B ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The United States ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Review Panel ◽  
B Virus ◽  
Escape Mutants

Abstract Background Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs (PWID) are at a higher risk of HBV infection and since 2009 three states (KY, TN, WV) have reported up to a 114% increase in cases of acute HBV infection due to higher infection rates among a non-Hispanic white populations (30–39 years), and injection drug users2. Hepatitis B vaccination is recommended as primary prevention for adults who are at increased risk for HBV infection, including PWID. However, data from the National Health Interview Survey indicate that hepatitis B vaccination coverage is low among adults in the general population3, and it is likely to be lower among injection drug users. Hepatitis B Surface Antigen (HBsAg) is the first serological marker to appear after HBV exposure and infection; this marker is included in the recommended panel for acute hepatitis diagnosis and accurate detection is necessary for early and accurate diagnosis. Serological testing challenges exist for HBsAg due to the high degree of genetic variability which can further be exacerbated by endogenous and exogenous pressures. The immuno-dominant region may have one or more mutations described as immune escape mutations which can decrease or abrogate HBsAg binding to antibodies used in immunoassays. Although the prevalence of these mutations is not well documented in the United States, international studies have shown that up to 79% of HBV-reactivated patients (vs 3.1% of control patients; p&lt; 0.001) carry HBsAg mutations localized in immune-active HBsAg regions4. Methods A study was conducted using a panel of 10 unique recombinant HBsAg immune escape mutants. Panel members were tested by commercially available HBsAg serological immunoassays. Results It was found that although commercially available HBsAg immunoassays are the primary diagnostic tool for HBV diagnosis, not all HBsAg immune escape mutants are detected, with some method detecting as few as 5 out of 10 of these mutant samples. Figure 1 Conclusion Improvement is needed in commercially available methods for the accurate detection of HBsAg. Disclosures Robert Gish, MD, Abbott (Consultant)AbbVie (Consultant, Advisor or Review Panel member, Speaker’s Bureau)Access Biologicals (Consultant)Antios (Consultant)Arrowhead (Consultant)Bayer (Consultant, Speaker’s Bureau)Bristol Myers (Consultant, Speaker’s Bureau)Dova (Consultant, Speaker’s Bureau)Dynavax (Consultant)Eiger (Consultant, Advisor or Review Panel member)Eisai (Consultant, Speaker’s Bureau)Enyo (Consultant)eStudySite (Consultant, Advisor or Review Panel member)Exelixis (Consultant)Fujifilm/Wako (Consultant)Genentech (Consultant)Genlantis (Consultant)Gilead (Consultant, Advisor or Review Panel member, Speaker’s Bureau)GLG (Consultant)HepaTX (Consultant, Advisor or Review Panel member)HepQuant (Consultant, Advisor or Review Panel member)Intercept (Consultant, Speaker’s Bureau)Ionis (Consultant)Janssen (Consultant)Laboratory for Advanced Medicine (Consultant)Lilly (Consultant)Merck (Consultant)Salix (Consultant, Speaker’s Bureau)Shionogi (Consultant, Speaker’s Bureau)Viking (Consultant)

scholarly journals Future Healthcare Workers and Hepatitis B Vaccination: A New Generation

2021 ◽  
Vol 18 (15) ◽  
pp. 7783
Author(s):  
Andrea Trevisan ◽  
Paola Mason ◽  
Annamaria Nicolli ◽  
Stefano Maso ◽  
Marco Fonzo ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Antibody Titer ◽  
Healthcare Workers ◽  
Lower Percentage ◽  
Hepatitis B Vaccination ◽  
High Morbidity ◽  
One Year ◽  
Mandatory Vaccination ◽  
University Of Padua ◽  
The University

Before the introduction of universal vaccination, hepatitis B caused high morbidity and mortality, especially among healthcare workers. In the present study, the immune status against hepatitis B was assessed in a cohort of 11,188 students of the degree courses of the School of Medicine of the University of Padua (Italy) who had been subjected to mandatory vaccination in childhood or adolescence and who will be future healthcare workers. The variables that influence the antibody response to vaccination are mainly the age at which the vaccine was administered and sex. If vaccination was administered before one year of age, there is a high probability (around 50%) of having an antibody titer lower than 10 IU/L compared to those vaccinated after one year of age (12.8%). The time between vaccine and analysis is not decisive. Furthermore, female sex, but only if vaccination was administered after one year of age, shows a significant (p = 0.0008) lower percentage of anti-HBs below 10 IU/L and a greater antibody titer (p < 0.0001). In conclusion, the differences related to the age of vaccination induce more doubts than answers. The only plausible hypothesis, in addition to the different immune responses (innate and adaptive), is the type of vaccine. This is not easy to verify because vaccination certificates rarely report it.

scholarly journals Occupational Sharp Injury and Splash Exposure among Healthcare Workers in a Tertiary Hospital

2021 ◽  
Author(s):  
Roshan Mathew ◽  
Ritin Mohindra ◽  
Ankit Sahu ◽  
Rachana Bhat ◽  
Akshaya Ramaswami ◽  
...  
Keyword(s):  
Emergency Department ◽  
Hepatitis B ◽  
Healthcare Workers ◽  
Hepatitis B Surface Antigen ◽  
Tertiary Hospital ◽  
Needle Stick Injury ◽  
Medical Procedures ◽  
Immunodeficiency Virus ◽  
History Of ◽  
Hepatitis C Virus Antibody

Abstract Background Occupational hazards like sharp injury and splash exposure (SISE) are frequently encountered in health-care settings. The adoption of standard precautions by healthcare workers (HCWs) has led to significant reduction in the incidence of such injuries, still SISE continues to pose a serious threat to certain groups of HCWs. Materials and Methods This was a retrospective study which examined the available records of all patients from January 2015 to August 2019 who self-reported to our emergency department with history of sharp injury and/or splash exposure. Details of the patients, mechanism of injury, the circumstances leading to the injury, status of the source (hepatitis B surface antigen, human immunodeficiency virus, and hepatitis C virus antibody status), and the postexposure prophylaxis given were recorded and analyzed. Data were represented in frequency and percentages. Results During the defined period, a total of 834 HCWs reported with SISE, out of which 44.6% were doctors. Majority of the patients have SISE while performing medical procedures on patients (49.5%), while 19.2% were exposed during segregation of waste. The frequency of needle stick injury during cannulation, sampling, and recapping of needle were higher in emergency department than in wards. More than 80% of HCWs received hepatitis B vaccine and immunoglobulin postexposure. Conclusion There is need for periodical briefings on practices of sharp handling as well as re-emphasizing the use of personal protective equipment while performing procedures.

Sign in / Sign up

Export Citation Format

Share Document